Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00502528
Status:
COMPLETED
Last Update Posted:
2013-04-30
First Post:
2007-07-16
Brief Title:
Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background and Objective Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI
Patients are randomized to receive periinterventional intravenous BQ-123 or placebo
Patients are randomized to receive periinterventional intravenous BQ-123 or placebo
Detailed Description:
Background and Objective Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels We have previously shown that thrombectomy in ST-elevation myocardial infarction STEMI accelerates ST-segment resolution possibly by preventing distal embolization Therefore we analyzed the vasoconstrictor concentration of acute coronary thrombi and found high concentrations of endothelin ET which correlated with the magnitude of ST-segment resolution within one hour of percutaneous coronary intervention PCI Furthermore ET-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from STEMI patients
The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI
Methods Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography
The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI
Methods Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None